ReviewIndian journal of clinical biochemistry : IJCB2013
First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
Review in Indian journal of clinical biochemistry : IJCB, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Diagnostic performance of PAPP-A and β-hCG in early detection of gestational diabetes mellitus: a meta-analysis.Acta diabetologica · 2026Pooled it
- First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis.PloS one · 2018Pooled it
- Article
- The Association between Serum Biochemical Markers and Early Amniocentesis in Diagnosing Chromosomal Anomalies: A Cross-Sectional Study in Southern Iran, 2021-2022.Iranian journal of medical sciences · 2026Article
- Low pregnancy-associated plasma protein-A and serum urotensin-II in 11-14 weeks gestation: case-control study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Prediction of birthweight with early and mid-pregnancy antenatal markers utilising machine learning and explainable artificial intelligence.Scientific reports · 2025Article
- Evaluating the Effectiveness of Quantitative Fluorescent Polymerase Chain Reaction as a Substitute or Complement to Conventional Karyotyping for Prenatal Diagnosis.Journal of obstetrics and gynaecology of India · 2025Article
- Exploring free pregnancy associated plasma protein a (fPAPP-A) as a biomarker in early pregnancy.Practical laboratory medicine · 2024Article
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.Journal of biomedical science · 2024Review
- Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis.Biomedicines · 2023Review
- COMBINED FIRST TRIMESTER SCREENING FOR FETAL DOWN SYNDROME AT THE SPLIT UNIVERSITY HOSPITAL CENTER: A SEVEN-YEAR EXPERIENCE.Acta clinica Croatica · 2023Review
- The effect of a vanishing twin on first- and second-trimester maternal serum markers and ultrasound screening for aneuploidy.Obstetrics & gynecology science · 2023Article
- First Trimester Screening Tests Pregnancy and Trisomy 13 Syndrome, Sex Chromosome Aneuploidy in Iran: A Cross-Sectional Study.International journal of fertility & sterility · 2023Article
- Article
- Prenatal screening tests and prevalence of fetal aneuploidies in a tertiary hospital in Thailand.PloS one · 2023Article
- Cell-Free Fetal Deoxyribonucleic Acid (cffDNA) Analysis as a Remarkable Method of Non-Invasive Prenatal Screening.Cureus · 2022Review
- Review
- Behavior of the Genetic Markers at Screening during the First Trimester of Pregnancy in Euploid Fetuses.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- PAPPA Expression in Indeterminate Thyroid Nodules as Screening Test to Select Patients for Molecular Testing.International journal of molecular sciences · 2022Article
- The Relationship between Screening Markers in the First Trimester of Pregnancy and Chromosome Aberrations.International journal of preventive medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies. This screening is done by a combination of two biochemical markers i.e. serum free β-human chorionic gonadotrophin (free β-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT) thickness at 11 + 0-13 + 6 weeks of gestation. A beneficial consequence of screening is the early diagnosis or trisomies 21, 18 and 13. At 11 + 0-13 + 6 weeks, the relative prevalence of trisomies 18 and 13 to trisomy 21 are found to be one to three and one to seven, respectively. All three trisomies are associated with increased maternal age, increased fetal NT and decreased PAPP-A, but in trisomy 21 serum free β-hCG is increased whereas in trisomies 18 and 13 free β-hCG is decreased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.